A Descazeaud

Publications (29)15.96 Total impact

• Article: [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: Guidelines of the LUTS committee of the French Urological Association].

  A Descazeaud, G Robert, N B Delongchamps, J-N Cornu, C Saussine, O Haillot, M Devonec, M Fourmarier, C Ballereau, B Lukacs, O Dumonceau, A R Azzouzi, A Faix, F Desgrandchamps, A de la Taille
  [show abstract] [hide abstract]
  ABSTRACT: To elaborate guidelines for the diagnosis, the follow-up, and the treatment of benign prostatic hyperplasia (BPH). A systematic review of the literature was conducted to select more relevant publications. The level of evidence was evaluated. Graded recommendations were written by a working group, and then reviewed by a reviewer group according to the formalized consensus technique. Terminology of the International Continence Society was used. Initial assessment has several aims: making sure that lower urinary tract symptoms (LUTS) are related to BPH, assessing bother related to LUTS and checking for a possible complicated bladder outlet obstruction (BOO). Initial assessment should include: medical history, LUTS assessment using a symptomatic score, physical examination including digital rectal examination, urinalysis, flow rate recording, and residual urine volume. Frequency volume chart is recommended when storage symptoms are predominant. Serum PSA should be done when the diagnosis of prostate cancer can modify the management. When a surgical treatment is discussed, serum PSA, serum creatinine and ultrasonography of the urinary tract are recommended. BPH patients should be informed of the benign and possibly progressive patterns of the disease. When LUTS cause no bother, annual follow-up should be planned. Medical treatment includes some phytotherapy agents, alpha-blockers and 5-alpha reductase inhibitors. The last two can be associated. The association of antimuscarinics and alpha-blockers can be offered to patients with residual storage symptoms when already under alpha-blockers therapy, after checking for the absence of severe BOO (residual volume more than 200mL or max urinary flow less than 10mL/s). Phosphodiesterase-5 inhibitors could be used in patients complaining for both LUTS and erectile dysfunction. In case of complication, or when medical treatment is inefficient or not tolerated, then a surgical treatment should be discussed. Treatment decision should be done according to type of LUTS and related bother, prostate anatomy, level of obstruction and its consequences on urinary tract, patient co-morbidities, experience of practitioner, and choice of patient. Surgical treatments with the higher level of evidence of efficacy include monopolar or bipolar transurethral resection of the prostate, open prostatectomy, transurethral incision of the prostate, photoselective vaporization of the prostate, and Holmium laser enuclation of the prostate. Here are the first guidelines of the French Urological Association for the initial assessment, the follow-up and the treatment of urinary disorders related to BPH.
  Progrès en Urologie 12/2012; 22(16):977-88. · 0.58 Impact Factor
• Article: [Surgical management of benign prostatic hyperplasia by endoscopic techniques using electricity and open prostatectomy: A review of the literature by the LUTS committee of the French Urological Association].

  N-B Delongchamps, G Robert, A Descazeaud, J-N Cornu, A-R Azzouzi, O Haillot, M Devonec, M Fourmarier, C Ballereau, B Lukacs, O Dumonceau, C Saussine, A de la Taille
  [show abstract] [hide abstract]
  ABSTRACT: To perform an update on the surgical treatment of benign prostatic hyperplasia (BPH) by endoscopic electric resection and vaporization, and by open prostatectomy. A systematic review of recent literature was performed. The level of evidence of each report was evaluated, and only recent publications of high level of evidence were included. Both monopolar transurethral resection of the prostate (TURP) and open prostatectomy remain the gold standards. Endoscopic electric alternatives are monopolar and bipolar prostate vaporisation as well as bipolar resection. These techniques seem to show similar functional results than TURP and open prostatectomy, as well as an advantage in terms of bleeding.
  Progrès en Urologie 02/2012; 22(2):73-9. · 0.58 Impact Factor
• Article: [Surgical management of BPH by laser therapies: A review of the literature by the LUTS committee of the French urological association].

  N Barry Delongchamps, G Robert, A Descazeaud, J-N Cornu, A Rahmene Azzouzi, O Haillot, M Devonec, M Fourmarier, C Ballereau, B Lukacs, O Dumonceau, C Saussine, A de la Taille
  [show abstract] [hide abstract]
  ABSTRACT: To perform an update on the surgical treatment of benign prostatic hyperplasia (BPH) by laser. A systematic review of recent literature was performed. The level of evidence of each report was evaluated, and only recent publications of high level of evidence were included. Monopolar transurethral resection of the prostate (TURP) and open prostatectomy remain the gold standards. Alternative endoscopic options are laser photoselective vaporisation, holmium enucleation and thulium resection. These techniques seem to show functional results similar to those obtained after TURP and open prostatectomy, as well as an advantage in terms of bleeding.
  Progrès en Urologie 02/2012; 22(2):80-6. · 0.58 Impact Factor
• Article: [Surgical management of benign prostatic hyperplasia by thermotherapy and other emerging techniques: A review of the literature by the LUTS committee of the French Urological Association].

  N Barry Delongchamps, G Robert, A Descazeaud, J-N Cornu, A R Azzouzi, O Haillot, M Devonec, M Fourmarier, C Ballereau, B Lukacs, O Dumonceau, C Saussine, A de la Taille
  [show abstract] [hide abstract]
  ABSTRACT: To perform an update on mini-invasive surgical treatment of benign prostatic hyperplasia (BPH) by thermotherapy and other emerging techniques. A systematic review of literature was performed in Pubmed database for the period running from 1980 to 2011. The level of evidence of each report was evaluated, and only recent publications of high level of evidence were included. Monopolar transurethral resection of the prostate (TURP) and open prostatectomy remain the gold standards. Thermotherapy using transurethral microwaves or needle ablation is an alternative to medical management. Urethral stents should only be proposed in exceptional cases of surgical contra-indication, because of their related complications. Botulinium toxin and ethanol intra-prostatic injections are currently under evaluation.
  Progrès en Urologie 02/2012; 22(2):87-92. · 0.58 Impact Factor
• Article: [Management of patients with long term indwelling catheter: Survey of Limousin general practitioners].

  E Valgueblasse, J Berger, A Roux, X Plainard, J-P Dumas, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the management of patients with long-term (>1 month) indwelling catheter by general practitioners (GP). A self-questionnaire was sent to 603 regional GP, between March and May 2010. It was composed of 12 multiple-choice questions and one open question, about management of their patients with indwelling catheter. Two hundred and twenty-eight self-questionnaires were analyzed: 126 (55%) from urban GP and 102 (45%) from rural GP. On average, each GP managed 1.3 patients with long term indwelling catheter (>1 month). The catheters were changed by the GP, urologists, and nurses in 23.2, 23.7, and 53.1%, respectively. In a majority of cases, catheters were changed every 4 weeks (59%). Nursing cares were prescribed by 64.5% of GP. Prescribed drainage bags were sterile in 42.5%. Most of GP reported to prescribe a daily change of drainage bag (56.1%). Urine analysis as performed only in case of symptomatic urine infection by 58% of respondents. Fifty percent of GP required guidelines for the management of patients with long term indwelling catheter. Rural GP managed significantly more patients with indwelling catheter, prescribed fewer sterile drainage bags, made change the drainage bag less often, and required the help of urologist less frequently. Management of long term indwelling catheter was heterogeneous among GP, and varied according to rural or urban practice. Some used significantly differed from available practice guidelines. This survey could be a basis for the preparation of an informative document aimed at GP.
  Progrès en Urologie 02/2012; 22(2):106-12. · 0.58 Impact Factor
• Article: [Initial assessment and follow-up of benign prostatic hyperplasia: systematic review of the literature by the LUTS committee of the French Urological Association].

  A Descazeaud, G Robert, N B Delongchamps, J-N Cornu, C Saussine, O Haillot, M Devonec, M Fourmarier, C Ballereau, B Lukacs, O Dumonceau, A R Azzouzi, A de la Taille
  [show abstract] [hide abstract]
  ABSTRACT: To perform an update on the initial evaluation and follow-up of benign prostatic hyperplasia (BPH). A systematic review of recent literature was performed. Level of evidence of publications was evaluated. Objectives of the initial evaluation are to assess the link between low urinary tract symptoms (LUTS) and BPH, to evaluate the bother associated to LUTS, assess a complicated bladder outlet obstruction (BOO), diagnose an adenocarcinoma of the prostate if it modifies the therapeutic strategy, and establish an evolutive profile of the disease. Clinical assessment with digital rectal examination, evaluation of symptoms by a dedicated questionnaire and urine analysis are the first steps of BPH evaluation. Bladder diary is useful to objective storage symptoms. Uroflowmetry and post-void residual volume assessment are useful if BOO is suspected. Measure of serum creatinine and ultrasound exam of the urinary tract are second line explorations. Urine cytology, neurological evaluation, urethrocystoscopy, urodynamics with pressure-flow studies are useful if the link between LUTS and BPH is unclear. PSA dosage is used for prostate cancer screening or as a prognostic marker of BPH evolution.
  Progrès en Urologie 01/2012; 22(1):1-6. · 0.58 Impact Factor
• Article: [Benign prostatic hyperplasia medical treatment: systematic review of the literature by the CTMH/AFU].

  G Robert, A Descazeaud, N Barry Delongchamps, J-N Cornu, A R Azzouzi, O Haillot, M Devonec, M Fourmarier, C Ballereau, B Lukacs, O Dumonceau, C Saussine, A de la Taille
  [show abstract] [hide abstract]
  ABSTRACT: The medical treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS-BPH) has dramatically evolved within the last years: new drugs have been commercialized and others that used to be contra-indicated may now be prescribed. Our objective was to provide with an updated review of the scientific literature on the medical treatment of LUTS-BPH. A systematic review of the most recent scientific literature was performed. The query was addressed to the PubMed database using the following keywords: "benign prostatic hyperplasia" and "medical treatment". A very large amount of publications, from year 1990 until 2011, were reviewed to select the publications with level of evidence 1 and 2. These publications were analysed and the 30 most relevant were selected to serve as references for this article. There are many randomized clinical trials in the field of LUTS-BPH medical treatment. Recently, anti-muscarinic agents have been assessed and have proven their efficacy and tolerance as long as the storage symptoms are predominant over the voiding symptoms. Combination therapies using alpha-blockers and 5-alpha reductase (5-ARI) inhibitors, but also anti-muscarinic agents and PDEF-5 inhibitors may also be prescribed depending on the patient' complaint. The publication of recent randomized clinical trials allows the urologists to use new drugs and new combination therapies in the medical treatment of LUTS-BPH. In 2011, the medical treatment decision-making may better integrate the patient' complaint and medical history.
  Progrès en Urologie 01/2012; 22(1):7-12. · 0.58 Impact Factor
• Article: [Transurethral needle ablation Prostiva for treating symptomatic benign prostatic hyperplasia: a review].

  E Xylinas, S Le Gal, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: Benign prostatic hyperplasia (BPH) is a common disease affecting a large proportion of men older than 50 years. There are multiple treatment options for BPH including medications, minimally invasive options such as transurethral needle ablation (Tuna) and transurethral microwave therapy (TUMT), and more invasive options such as transurethral laser vaporization and transurethral resection of the prostate (TURP). The minimally invasive options induce thermal injury to the BPH adenoma with a lower risk of permanent side effects than TURP. Tuna treatment is a minimally invasive technique of BPH which can be carried out in ambulatory surgery and which is effective for urinary symptoms with little risk of morbidity. It is an alternative to medical treatment and does not replace planned surgical treatment. Available evidence suggests that Tuna is a relatively effective and safe technique. It significantly improves BPH parameters but it does not reach the same level efficacy and long-lasting success as TURP. Also the Tuna procedure compares favourably to combination medical therapy for the treatment of BPH on a cost basis. α-Blocker monotherapy is less costly than Tuna for 5 years, while the cost of 5α-reductase inhibitor monotherapy is approximately equivalent to that of Tuna for 5 years. From the payer's perspective, the break-even point between the Tuna(®) procedure and combination medical management occurs after approximately 2 years 7 months of treatment.
  Progrès en Urologie 09/2010; 20(8):566-71. · 0.58 Impact Factor
• Article: [Medical treatment of BPH].

  A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: Four therapeutic classes can be used for the treatment of BPH: alphablockers, 5 alpha reductase inhibitors (5ARI), muscrinic receptor antagonists, and plant extracts. Two combination therapies have been proven to be efficient: 5ARI - alphablockers, and muscarinic receptor antagonists - alphablockers. Alphablockers have the advantage to be efficient quickly. 5ARI decrease prostate volume. Efficacy of plant extracts is still discussed, but their tolerance is excellent. Muscrinic receptor antagonists can be a viable treatment option for men with predominantly bladder storage symptoms but without bladder outlet obstruction.
  Progrès en Urologie 12/2009; 19(12):890-2. · 0.58 Impact Factor
• Article: [Male stress urinary incontinence by InVance bone anchored sub-urethral sling: Predictive factors of treatment failure: Multicentric study by the CTMH-AFU].

  M Lanoe, C Saussine, P Mouracade, A R Azzouzi, M Devonec, A Ruffion, G Robert, A de la Taille, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: To define predictive factors of treatment failure in a multicentric study for the treatment of stress male urinary incontinence by InVance (American Medical System, USA) bone anchored sub-urethral sling. Cases treated by InVance between January 2005 and December 2007 in four French academic centers were collected. Eighty-four patients were evaluated. Mean age was 68 years old. With a mean follow-up of 20 months, 38 patients (45%) were dry, 22 (26%) were improved, and 24 (29%) suffered treatment failure. In univariate analysis, three parameters were significantly associated with treatment failure, including severe urinary incontinence (P=0.005), urodynamic instability (P=0.043), and incontinence due to a bitherapy including external radiotherapy (P=0.031). If zero or one versus two or three risk factors were present, treatment failure rate was 25 and 67%, respectively (P=0.013). In multivariate analysis, bitherapy including radiotherapy was the sole independent treatment failure risk factor (P=0.017). Two patient groups were defined, allowing to determine preoperatively good candidates and bad candidates for stress urinary incontinence treatment by InVance sling.
  Progrès en Urologie 12/2009; 19(11):839-44. · 0.58 Impact Factor
• Article: [Benign prostatic hyperplasia surgery and anticoagulant therapy: review of the literature by the French Association of Urology].

  G Robert, A Descazeaud, A R Azzouzi, C Saussine, O Haillot, O Dumonceau, C Ballereau, M Fourmarier, M Devonec, B Lukacs, F Desgrandchamps, A de la Taille
  [show abstract] [hide abstract]
  ABSTRACT: The prescription of a long-term oral anticoagulant may pose several problems for the endoscopic surgery of benign prostatic hyperplasia (BPH). Questions regarding the length of its interruption, what it can be replaced by and the date oral treatment can be resumed must be asked at preoperative stage to avoid haemorrhaging or cardiovascular accidents. While the number of patients concerned by this type of prescription continues to grow, surgical hemostasis techniques continue to progress and recommendations for good practice are evolving. It is therefore interesting to bring up to date the knowledge and recommendations for surgery of BHP while being treated with anticoagulants. A systematic revue of publications and of recommendations by knowledgeable bodies in cardiology and anesthesia were carried out. The transurethral resection of the prostate (TURP) is an intervention which carries an intermediate risk of haemorrhaging. Whenever possible, it is recommended to briefly interrupt the anticoagulant treatment in the perioperative period. For antivitamins K, heparinotherapy takes over, which, thanks to a short half-life, allows for a quicker management of the anticoagulation. For antiplatelets, the tendency is towards proposing an interruption for 4 to 5 days before the intervention. In all cases, the anticoagulant must be reintroduced as quickly as possible because cardiovascular risks are in proportion to the length of time of interruption. The strategy for treatment of patients taking oral anticoagulants is complex. It must be defined in consultation with the anesthetist, the cardiologist or hemostatis specialist. Nevertheless, the urologist remains at the center of the decision for treatment because he/she is the only one who can weigh up the risk of haemorrhaging, the cardiovascular risks and the necessity of an operation and technique used.
  Progrès en Urologie 10/2009; 19(8):517-23. · 0.58 Impact Factor
• Article: [Repeat midurethral sling for female stress urinary incontinence after failure of the initial sling].

  E Xylinas, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: Midurethral sling (MUS) is the gold standard treatment of female stress urinary incontinence (SUI). No consensus exists regarding the way to manage patients who have persistent or recurrent SUI following MUS. The aim was to evaluate the use of a second MUS for the treatment of persistent or recurrent SUI following a first MUS. Literature review based on keywords: "stress urinary incontinence", "tape", "failure", "second MUS". Fifty-one cases of second MUS were identified within five studies. No major complication was reported. The success rate of second MUS ranged from 76 to 100% with a median follow-up of 5 to 22 months. The use of a retropubic approach for the repeat MUS could be more efficient than the transobturator way. The repeat MUS for persistent or recurrent SUI appears to be a safe and efficient therapeutic option. Further studies with larger number of patients and longer follow-up are needed to reach definite conclusions.
  Progrès en Urologie 10/2009; 19(9):590-4. · 0.58 Impact Factor
• Article: [Analysis of anatomopathological results of radical prostatectomy specimen of patients who answer to criteria for active surveillance of prostate cancer].

  V Azancot, M Peyromaure, E Xylinas, A Descazeaud, F Cornud, A Vieillefond, D Saighi, D Amsellem-Ouazana, B Debré, M Zerbib
  [show abstract] [hide abstract]
  ABSTRACT: To analyze pathological data of the radical prostatectomy specimen in patients operated for clinically-localized prostate cancer and who meet strict criteria for active surveillance. The data of patients who underwent a radical prostatectomy by a single surgeon between 2002 and 2007 were reviewed. We only included the patients that met the usual criteria for active surveillance: clinical stage T1-2a tumor, PSA< or =10 ng/mL, biopsy Gleason sum inferior or equal to 6 with no pattern of grade 4 or 5, cancer involvement inferior or equal to two biopsy cores, inferior to 50% of malignant tissue in each positive biopsy core and a PSA density inferior or equal to 0.15 ng/ml/cc. Two hundred and seventy-three patients were operated, including 25 (9.2%) who met all the criteria for active surveillance. Mean age was 61 years (55-68). The mean preoperative PSA was 6.6 ng/mL (2.5-10). Clinical stage of the tumor was T1c in 84% of patients and T2a in 16%. Biopsy Gleason score was 3+3 in 92%, 2+3 in 4% and 2+2 in 4%. Pathological study of the surgical specimen showed that 28% of the tumors were pT2a, 8% pT2b, 40% pT2c and 20% pT3a. One tumor was pT0. The pathological Gleason score was 3+3 in 68% of patients and 3+4 in 28%. Surgical specimen showed a higher Gleason score in 44% of cases, but there were no cases of predominant grade 4. After a mean follow-up of 19.2 months, there was no clinical or biological recurrence. In our experience, 20% of patients who meet the criteria for active surveillance show an extracapsular extent of the tumor on pathological analysis. Active surveillance is still under evaluation. Its main risk is to underestimate the aggressiveness of the tumor at the time of diagnosis.
  Progrès en Urologie 10/2009; 19(9):619-23. · 0.58 Impact Factor
• Article: [Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].

  A Descazeaud, J-P Mignard, J-L Davin, J Irani
  [show abstract] [hide abstract]
  ABSTRACT: To survey the French urologists in order to evaluate their practice of BCG and mitomycin C instillations in the treatment of non muscle invasive bladder tumours (NMIBT). The survey was performed in 2008 on French urologists registered by the French Urological Association (AFU), using online self-administered questionnaires. One hundred and fifty-six urologists answered the questionnaire. The majority of responders reported indications for bladder instillations that were closed to the AFU recommendations, but for 25% of the respondents, indications were far away from the recommendations. Seventy-nine percent of respondents said that first line plus maintenance BCG therapy was more efficient than first line alone. However, many of the respondents reported that maintenance BCG therapy was not well accepted by patients (46%), was not easy to organize (28%), and was not well tolerated by patients (56%). Eighty-eight percent of respondents said using ofloxacin to prevent BCG adverse effects, but the protocol they were using was not clearly defined. Definition of BCG therapy failure given by respondents was close to the AFU one, but the way to manage it was heterogeneous. Responses of the 156 urologists who took part in this survey should help to evaluate French urologists attitude toward bladder instillations in the treatment of NMIBT. Although they were not so far from the AFU recommendations, urologists' practices of instillations appeared to be heterogeneous. Some points requiring clarification were highlighted in this study.
  Progrès en Urologie 10/2009; 19(9):624-31. · 0.58 Impact Factor
• Article: [Management of patients under anticoagulants for transurethral resection of the prostate: a multicentric study by the CTMH-AFU].

  S Lebdai, G Robert, M Devonnec, M Fourmarier, O Haillot, C Saussine, A R Azzouzi, A De La Taille, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: To determine how are managed patients with anticoagulation treatments who are operated by transuretral resection of the prostate (TURP), and to evaluate the morbidity associated to these treatments. This is a retrospective study on 226 patients operated consecutively in six french hospitals between January 2007 and August 2008 by TURP for symptomatic benign prostatic hypertrophy (BPH). Eighty-three patients (37%) operated by TURP were under anticoagulation treatment before hospitalization. (23 cases under coumarin derivatives, 57 cases under platelet aggregation inhibitors, and three cases under low molecular weight heparin). Management of anticoagulation for the operative period was very heterogenic. Overall, patients under anticoagulation treatment had significantly longer hospitalization period (5.8 versus 4.9 days, p = 0.003) and were more frequently re-hospitalized for hematuria (14.5% versus 1.4%, p < 0.001). Considering early and late morbidity, no significant difference was observed between patients under coumarin derivatives and those under platelet aggregation inhibitors. This study assessed the risk of anticoagulants in BPH surgery, and showed the necessity of establishing protocols and recommendations for the management of patients under anticoagulation treatment requiring BPH surgery.
  Progrès en Urologie 09/2009; 19(8):553-7. · 0.58 Impact Factor
• Article: [Preoperative factors of misdiagnosis of renal angiomyolipoma].

  J Berger, E Valgueblasse, J Thereaux, X Plainard, A Bouhlel, M Lanoe, F Paraf, F Cornu, J-P Dumas, T Flam, M Zerbib, B Debre, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: To explain the high incidence of misdiagnosis of angiomyolipoma (AML) prior to surgery. Between 1989 and 2007, 2,657 patients were operated for a renal tumor at Dupuytren hospital in Limoges and at Cochin hospital in Paris. In 85 cases (3.2%), tumors were AMLs on pathology. The group of patients in which the diagnosis was done preoperatively was compared to the one in which the diagnosis was missed. Mean age of patients was 57-years-old and the sex-ratio was five women for one man. The mean size of AMLs was 5.4 cm. The patients were symptomatic in 46% of cases (39/85). The diagnosis of AML was ignored preoperatively in 62 patients (73%). In multivariate analysis, the small size of the AML, low proportion of fat and male sex were significantly associated with misdiagnosis of AML (p<0.001, p<0.018 and p<0.008, respectively). The incidence of misdiagnosis of AML preoperatively is high. The diagnosis seems particularly difficult when the tumor is small or contains a small proportion of fat. In addition, this study highlights that the diagnosis of AML is frequently ignored in men. The increased resolution of CTscan and the use of preoperative biopsies for tumors less than 4 cm could be helpful to decrease the incidence of useless surgery of AMLs.
  Progrès en Urologie 06/2009; 19(5):301-6. · 0.58 Impact Factor
• Article: [Testicular implants, patient's and partner's satisfaction: a questionnaire-based study of men after orchidectomy].

  E Xylinas, G Martinache, V Azancot, D Amsellem-Ouazana, D Saighi, T Flam, M Zerbib, B Debré, M Peyromaure, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: To assess the satisfaction of men and of their partner towards their testicular implants after undergoing orchidectomy. Hundred and twenty-four consecutive patients, who had undergone orchidectomy, and their partner were sent an anonymous questionnaire. The follow-up after the implantation was at least one year. The testicular implants used were all Perthèse. Seventy-two patients answered to the questionnaire, among whom 63 had a testicular implant. Fifty-eight partners answered. From the patients with implant, 5% thought their body image was worse than before the operation and 80% thought their sexual activity was unchanged. Ninety-six percent thought the implantation was worthwhile and would do it again if they had to do the choice again. The reasons for dissatisfaction were: for the shape (n=8), for the size (n=3), for the position (n=2) and one patient thought the implant was too cold. Forty percent of the partners did not care about the implants and 58% thought the implant was essential. The dissatisfaction rate for the partners was 26% and reasons for were: for the shape (n=5), for the size (n=2), and one partner thought the implant was too cold. From the patients without implant, only one is thinking about having one. Testicular implants are well accepted, but some reasons of dissatisfaction appeared in our study. It was the first evaluation of the partner's satisfaction.
  Progrès en Urologie 01/2009; 18(13):1082-6. · 0.58 Impact Factor
• Article: [Cancers of the penis and testicle: news in 2008].

  A Descazeaud, N Mottet
  [show abstract] [hide abstract]
  ABSTRACT: In the 2007 international conferences, a certain number of communications were devoted to the cancers of the male external genital organs. The most innovating studies were selected. In the pure testicular seminomas, radiotherapy was compared to carboplatin in adjuvant treatment. Active surveillance of stage Ia germinal tumors was evaluated. In penis cancer management, curietherapy in early-stage treatment was reported, and sentinel lymph node detection was covered in many studies.
  Progrès en Urologie 09/2008; 18 Suppl 6:S130-4. · 0.58 Impact Factor
• Article: [Kidney cancer: news in 2008].

  J-J Patard, E Lechevallier, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: The most innovating studies presented at the 2007 international conferences in the field of kidney cancer were selected. The notable topics presented covered diagnostic biopsies and the growing place of conservative surgery and laparoscopy in kidney cancer management. For cases with poor prognosis, the new anti-angiogenic therapies were thoroughly evaluated.
  Progrès en Urologie 09/2008; 18 Suppl 6:S135-40. · 0.58 Impact Factor
• Article: [Bladder cancer: news in 2008].

  J Irani, A Descazeaud
  [show abstract] [hide abstract]
  ABSTRACT: In 2007, urothelial cancers were the subject of a large number of varied communications in international conferences. Some of the most innovating studies likely to modify patient management were selected. Regarding non muscle-invading tumors, maintenance treatments using intravesical instillations were emphasized. Laser and laparoscopy were assessed in urothelial tumors of the upper urinary tract. Finally, new radiochemotherapy protocols have appeared for infiltrating bladder tumors. Extended lymphadenectomy and laparoscopy were also evaluated in detail.
  Progrès en Urologie 09/2008; 18 Suppl 6:S125-9. · 0.58 Impact Factor